Systemic inflammation, cachexia and prognosis in patients with cancer - PubMed (original) (raw)

Review

Systemic inflammation, cachexia and prognosis in patients with cancer

Christopher Deans et al. Curr Opin Clin Nutr Metab Care. 2005 May.

Abstract

Purpose of review: Cachexia remains an important cause of morbidity and mortality among cancer patients. The mechanisms underlying this syndrome remain unclear and are almost certainly multifactorial. Evidence from animal models suggests a compelling link between cachexia and inflammation, and a variety of pro-inflammatory cytokines play an integral role. This review summarizes current thinking relating to inflammation, cachexia and prognosis in cancer patients, with particular emphasis on studies relating to recent therapeutic advances.

Recent findings: Pro-inflammatory cytokines induce the acute phase protein response, a key marker of systemic inflammation. Recent evidence has also implicated other tumour-derived mediators, such as proteolysis-inducing factor and parathyroid hormone-related peptide. In addition, systemic inflammation has been found in association with many malignancies, and has been correlated with weight loss, hypermetabolism, anorexia, and adverse prognosis. Treatments such as fish oil, monoclonal antibodies, and non-steroidal anti-inflammatory drugs, have all been utilized to attenuate systemic inflammation and influence weight loss. Recent clinical studies have suggested that eicosapentaenoic acid and cyclo-oxygenase 2 inhibitors promote weight gain and downregulate the acute phase protein response.

Summary: Pro-inflammatory processes are clearly implicated in the hypermetabolism and weight loss associated with cancer-associated cachexia. In addition, the presence of systemic inflammation is now clearly linked with adverse prognosis in patients with cancer, which cannot be fully explained by the association with weight loss. Systemic inflammation remains an important area for novel therapeutic targets in combating cachexia, and eicosapentaenoic acid and cyclo-oxygenase 2 inhibitors appear to be efficacious in the armory against cachexia.

PubMed Disclaimer

Similar articles

• Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia.
  Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T. Fearon KC, et al. World J Surg. 1999 Jun;23(6):584-8. doi: 10.1007/pl00012351. World J Surg. 1999. PMID: 10227928 Review.
• Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem.
  Winfield RD, Delano MJ, Pande K, Scumpia PO, Laface D, Moldawer LL. Winfield RD, et al. JPEN J Parenter Enteral Nutr. 2008 Nov-Dec;32(6):651-5. doi: 10.1177/0148607108325075. JPEN J Parenter Enteral Nutr. 2008. PMID: 18974247 Free PMC article. Review.
• The origins of cachexia in acute and chronic inflammatory diseases.
  Delano MJ, Moldawer LL. Delano MJ, et al. Nutr Clin Pract. 2006 Feb;21(1):68-81. doi: 10.1177/011542650602100168. Nutr Clin Pract. 2006. PMID: 16439772 Review.
• Cachexia, survival and the acute phase response.
  Stephens NA, Skipworth RJ, Fearon KC. Stephens NA, et al. Curr Opin Support Palliat Care. 2008 Dec;2(4):267-74. doi: 10.1097/SPC.0b013e3283186be2. Curr Opin Support Palliat Care. 2008. PMID: 19060563 Review.
• The Role of Tumor Microenvironment Cells in Colorectal Cancer (CRC) Cachexia.
  Kasprzak A. Kasprzak A. Int J Mol Sci. 2021 Feb 4;22(4):1565. doi: 10.3390/ijms22041565. Int J Mol Sci. 2021. PMID: 33557173 Free PMC article. Review.

Cited by

• Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia.
  Skorokhod A, Bachmann J, Giese NA, Martignoni ME, Krakowski-Roosen H. Skorokhod A, et al. BMC Cancer. 2012 Jun 21;12:265. doi: 10.1186/1471-2407-12-265. BMC Cancer. 2012. PMID: 22721276 Free PMC article.
• Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.
  Sakuma K, Yamaguchi A. Sakuma K, et al. J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):77-94. doi: 10.1007/s13539-011-0052-4. Epub 2012 Jan 12. J Cachexia Sarcopenia Muscle. 2012. PMID: 22476916 Free PMC article.
• Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling.
  Chen X, Wu Y, Yang T, Wei M, Wang Y, Deng X, Shen C, Li W, Zhang H, Xu W, Gou L, Zeng Y, Zhang Y, Wang Z, Yang J. Chen X, et al. J Cachexia Sarcopenia Muscle. 2016 May;7(2):225-32. doi: 10.1002/jcsm.12054. Epub 2016 Jan 18. J Cachexia Sarcopenia Muscle. 2016. PMID: 27493875 Free PMC article.
• JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
  Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. Rao TN, et al. Blood. 2019 Nov 21;134(21):1832-1846. doi: 10.1182/blood.2019000162. Blood. 2019. PMID: 31511238 Free PMC article.
• A prospective randomized comparative trial evaluating postoperative nutritional intervention in patients with oral cancer.
  Nett H, Steegmann J, Tollkühn-Prott B, Hölzle F, Modabber A. Nett H, et al. Sci Rep. 2022 Aug 20;12(1):14213. doi: 10.1038/s41598-022-18292-8. Sci Rep. 2022. PMID: 35987809 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program